Humulin
Humulin is a brand of human insulin produced by recombinant DNA technology and marketed by Eli Lilly and Company. It consists of human insulin identical to endogenous insulin and is used to treat diabetes mellitus in adults and children who require insulin therapy. Introduced in 1982, it was the first commercially available recombinant human insulin, helping to replace animal-derived insulins in many markets.
Formulations include Humulin R, a short-acting regular insulin; Humulin N, an intermediate-acting NPH insulin; and premixed
Administration and dosing vary by formulation and patient need; most Humulin products are administered by subcutaneous
Side effects include hypoglycemia (low blood glucose), weight gain, and injection-site reactions. Rare allergic reactions or